Exploring the Comparative Efficacy of Metformin and Resveratrol in the Management of Diabetes-Associated Complications: A Systematic Review of Preclinical Studies

Nutrients

KwaziB. Gabuza¹  PhiwayinkosiV. Dludla¹  Johan Louw¹  Rabia Johnson¹  ChristoJ. F. Muller¹  Luca Tiano²  Sonia Silvestri²  Patrick Orlando²  SithandiweE. Mazibuko-Mbeje³  Kabelo Mokgalaboni⁴  BonganiB. Nkambule⁴  TawandaM. Nyambuya⁴  Vuyolwethu Mxinwa⁴ 

[1] Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg 7505, South Africa;Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy;Division of Medical Physiology, Faculty of Health Sciences, Stellenbosch University, Private Bag X1, Tygerberg 7505, South Africa;School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa;

关键词: metformin;    resveratrol;    combination therapy;    diabetes mellitus;    dietary supplements;    antioxidants;   

DOI  :  10.3390/nu12030739

来源: DOAJ

【 摘 要 】

Food-derived bioactive compounds such as resveratrol are increasingly explored for their protective effects against metabolic complications. Evidence supports the strong antioxidant properties and therapeutic effects of resveratrol in managing diabetes and its associated complications. However, evidence informing on the comparative or combination effects of this natural compound with an accomplished and well-characterized antidiabetic agent like metformin has not been revised. Thus, we conducted a comprehensive systematic search of the major electronic databases which included MEDLINE, Cochrane Library, and EMBASE. The cumulative evidence strongly supports the comparative effects of metformin and resveratrol in ameliorating diabetes-associated complications in preclinical settings. In particular, both compounds showed strong ameliorative effects against hyperglycemia, dyslipidemia, insulin resistance, a pro-inflammatory response, and lipid peroxidation in various experimental models of diabetes. Enhancing intracellular antioxidant capacity in addition to activating NAD-dependent deacetylase sirtuin-1 (SIRT1) and AMP-activated protein kinase (AMPK) are the prime mechanisms involved in the therapeutic effects of these compounds. Of interest, preclinical evidence also demonstrates that the combination treatment with these compounds may have a greater efficacy in protecting against diabetes. Thus, confirmation of such evidence in well-organized clinical trials remains crucial to uncover novel therapeutic strategies to manage diabetes and its linked complications.

【 授权许可】

Unknown